02 Mar 2015

A potential single-dose cure for malaria

MMV390048 is a novel antimalarial compound belonging to the aminopyridine class. In combination with a partner drug, MMV390048 has the potential to become a new child-friendly treatment for uncomplicated malaria that could be given as one single dose, completing the treatment in just one day instead of the current three days.

This drug is currently being assessed in South Africa in healthy volunteers in a Phase I study led by Prof Karen Barnes from the University of Cape Town, and in a human challenge study being conducted by Prof James McCarthy at QIMR Berghofer Medical Research Institute in Brisbane, Australia.